Industry Reports
New Elsevier report highlights progress towards disease-modifying treatments for pancreatitis
Elsevier, a global leader in research publishing and information analytics, has published the findings from a new report on emerging trends for pancreatitis in the scientific literature. Acute pancreatitis is the most common GI-related cause for hospitalization in the...
Industry Reports
Oncology Is a Major Focus for Many AI Drug Discovery Companies, Reports IDTechEx
The application of artificial intelligence (AI) in the drug discovery process is promising to drastically cut down timelines and costs of bringing new therapies to patients. Typically, the development of a drug costs companies more than $1 billion, in...
Drug Research
Phesi Big Data Analysis of Over 200,000 Hepatitis B and C Patients Identifies Typical Patient to Help Drive Forward Disease Elimination Goals
Phesi Inc., a data-driven provider of AI-powered clinical development analytics products and solutions, has analyzed data from 209,860 hepatitis B (HBV) and C (HCV) patients, from 940 trial arms/cohorts to build a picture of the “typical” patient and identify...
Industry Reports
CPhI Report predicts record EBITDAs for CDMOs in 2022
Part one of the 2021 CPhI Annual Report predicts an increasingly bullish outlook for CDMOs in the next 2-3 years, with macro factors significantly driving up demand and prices for mergers and acquisitions. The full findings (featuring 10+ experts...
Industry Reports
Pharmapack Report 2021: US leads on drug device innovation but trails Europe on sustainability
Ahead of the first Pharmapack Europe to be held in nearly 18-months, Informa has released the results of its global drug delivery and packaging survey, with the USA once again leading ‘drug delivery and device innovation’, but lagging behind...
Industry Reports
Bachem reports excellent results for the first half-year 2021
Sales grow by 35.0% to CHF 239.1 million
EBITDA rises from CHF 53.0 million to CHF 75.5 million and a margin of 31.6%.
Operating income (EBIT) increases from CHF 40.3 million to CHF 61.9 million and a margin...
Industry Reports
Samsung Biologics Reports Strong SecondQuarter 2021 Financial Results
Samsung Biologics , a leading contract development and manufacturing organization, announced strong financial results for the secondquarter of fiscal 2021.
John Rim, CEO of Samsung Biologics, stated, “The second-quarter financial performance demonstrates our ability to maintain steady operations despite the...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
